Quantum Biopharma Ltd. (QNTM) Form 6-K — Aug 13, 2026
Quantum BioPharma (QNTM) furnished its Q2 and H1 2026 interim financials and MD&A on Form 6-K, reporting a Q2 net loss of $3.09 million ($(0.47) per share), sharply narrower than the $9.77 million loss ($(3.23)) in Q2 2025. The company ended June 30, 2026 with $3.65 million in cash and $5.89 million of digital assets against $8.30 million of total liabilities and a $215.1 million accumulated deficit, after using $3.46 million of cash in operations during the first half.
Key figures
- Total Assets
- 14391885
- Cash Position
- 3647072
- Shares Outstanding
- 7,577,120 Class B Subordinate Voting Shares (plus 42 Class A Multiple Voting Shares) as of June 30, 2026
- Digital assets
- 5887655
- Total liabilities
- 8297670
- Warrant liability
- 2227505
- Accumulated deficit
- 215099436
- Derivative liabilities
- 1726994
- Unbuzzd ownership percent
- 19.48%
- March 2026 debenture coupon
- 1.25% per month
- Notes payable due on demand
- 300549
- Atm shares issued six months
- 2127794
- Atm gross proceeds six months
- 8105022
- Atm subsequent gross proceeds
- 675823
- March 2026 debenture gross proceeds
- 2733109
AI analysis
Red flags9 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.